RxDoctor Payments Data

Phelps Lambert, MD

Family Medicine · Lansdale, PANPI 1083059406

Payments from drug & device makers

$9,482in general payments, 2019–2025

Across 592 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$845
  • Novo Nordisk$803
  • Lilly USA, LLC$630
  • GSK$575
  • Pfizer$393
  • plus $5K from 53 others

What the payments were for

  • Food & beverage$9,476100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,482 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$23,351
Medicare patients
150
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide23$37,207
OzempicSemaglutide27$33,214
EliquisApixaban25$25,884
JanuviaSitagliptin Phosphate17$22,191
JardianceEmpagliflozin21$22,077
XareltoRivaroxaban22$15,051
ShingrixVaricella-Zoster Ge/As01b/Pf14$3,150
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,128
Atorvastatin Calcium118$1,551
Rosuvastatin Calcium101$1,530
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide21$1,211
Losartan Potassium67$1,055
Tadalafil11$1,002
Lisinopril102$987
Metoprolol Succinate59$917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$630$37,20723 claims
Novo NordiskOzempic$803$33,21427 claims
PfizerEliquis$393$25,88425 claims
MerckJanuvia$367$22,19117 claims
Boehringer IngelheimJardiance$161$22,07721 claims
Johnson & JohnsonXarelto$83$15,05122 claims
GSKShingrix$575$3,15014 claims
AbbVieSynthroid$1,562$83211 claims
ANI Pharmaceuticals, Inc.Valsartan$18$60314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Lansdale

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →